<?xml version="1.0" encoding="UTF-8"?>
<p>Anti‐SARS COV‐2 antibody containing plasma, obtained from the recovered individuals who had confirmed COVID‐19, have been started to be collected by apheresis devices and stored in blood banks in some countries such as Turkey and the United States of America in hopes of reducing mortality rates and reduce the need of intensive care. Therefore, in this review, we aim to point out some important issues related to convalescent plasma (CP) and its use in COVID‐19.</p>
